Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Clinical scale synthesis of intrinsically radiolabeled and cyclic RGD peptide functionalized 198Au nanoparticles for targeted cancer therapy.

Chakravarty R, Chakraborty S, Guleria A, Kumar C, Kunwar A, Nair KVV, Sarma HD, Dash A.

Nucl Med Biol. 2019 May 29;72-73:1-10. doi: 10.1016/j.nucmedbio.2019.05.005. [Epub ahead of print]

PMID:
31255874
2.

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR.

Adv Ther. 2019 Jun 20. doi: 10.1007/s12325-019-00994-7. [Epub ahead of print]

PMID:
31222714
3.

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.

Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E.

Ann Clin Transl Neurol. 2018 Dec 9;6(2):252-262. doi: 10.1002/acn3.700. eCollection 2019 Feb.

4.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

PMID:
30635477
5.

Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis.

Trinkley KE, Anderson HD, Nair KV, Malone DC, Saseen JJ.

Ther Adv Chronic Dis. 2018 Jun 13;9(9):179-190. doi: 10.1177/2040622318779760. eCollection 2018 Sep.

6.

A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.

Rovner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, Gemmen E, Kristy RM, Gooch KL, Schermer CR.

Contemp Clin Trials. 2018 Jul;70:83-87. doi: 10.1016/j.cct.2018.05.006. Epub 2018 May 16.

7.

One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.

Effron MB, Nair KV, Molife C, Keller SY, Page RL 2nd, Simeone JC, Murphy B, Nordstrom BL, Zhu Y, McCollam PL, Vetrovec GW.

Am J Cardiovasc Drugs. 2018 Apr;18(2):129-141. doi: 10.1007/s40256-017-0255-y.

PMID:
29222628
8.

Beneficial effects of high dose taurine treatment in juvenile dystrophic mdx mice are offset by growth restriction.

Terrill JR, Pinniger GJ, Nair KV, Grounds MD, Arthur PG.

PLoS One. 2017 Nov 2;12(11):e0187317. doi: 10.1371/journal.pone.0187317. eCollection 2017.

9.

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.

Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E.

Mult Scler J Exp Transl Clin. 2017 Aug 17;3(3):2055217317725102. doi: 10.1177/2055217317725102. eCollection 2017 Jul-Sep.

10.

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.

Foley JF, Nair KV, Vollmer T, Stephenson JJ, Niecko T, Agarwal SS, Watson C.

Patient Prefer Adherence. 2017 Jun 16;11:1035-1048. doi: 10.2147/PPA.S134865. eCollection 2017.

11.

Two decades of glatiramer acetate: From initial discovery to the current development of generics.

Weinstock-Guttman B, Nair KV, Glajch JL, Ganguly TC, Kantor D.

J Neurol Sci. 2017 May 15;376:255-259. doi: 10.1016/j.jns.2017.03.030. Epub 2017 Mar 21. Review.

12.

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.

Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Harrington LA, Lin S, Ghuschcyan V, Nair KV, Everson GT.

Ann Hepatol. 2017 May - Jun;16(3):366-374. doi: 10.5604/16652681.1235479.

13.

Economic burden of comorbid chronic kidney disease and diabetes.

McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ.

J Med Econ. 2017 Jun;20(6):585-591. doi: 10.1080/13696998.2017.1288127. Epub 2017 Feb 14.

PMID:
28128669
14.

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.

Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Ayres Harrington L, Lin S, Ghuschcyan V, Nair KV, Everson GT.

Ann Hepatol. 2017 May - Jun;16(3):366-374. doi: 10.5604/01.3001.0009.8591.

15.

Incremental increases in economic burden parallels cardiometabolic risk factors in the US.

McQueen RB, Ghushchyan V, Olufade T, Sheehan JJ, Nair KV, Saseen JJ.

Diabetes Metab Syndr Obes. 2016 Aug 2;9:233-41. doi: 10.2147/DMSO.S106809. eCollection 2016.

16.

(90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.

Chakravarty R, Chakraborty S, Sarma HD, Nair KV, Rajeswari A, Dash A.

J Labelled Comp Radiopharm. 2016 Jul;59(9):354-63. doi: 10.1002/jlcr.3413. Epub 2016 Jun 5.

PMID:
27264196
17.

Image of the Month: Endoscopic Removal of an IUCD Migrated Into the Rectum.

Nair KV.

Am J Gastroenterol. 2016 Mar;111(3):309. doi: 10.1038/ajg.2015.265. No abstract available.

PMID:
27018103
18.

The cost of inpatient death associated with acute coronary syndrome.

Page RL 2nd, Ghushchyan V, Van Den Bos J, Gray TJ, Hoetzer GL, Bhandary D, Nair KV.

Vasc Health Risk Manag. 2016 Feb 3;12:13-21. doi: 10.2147/VHRM.S94026. eCollection 2016.

19.

Multiple sclerosis prevalence in the United States commercially insured population.

Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD.

Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.

20.

Palliative care of bone pain due to skeletal metastases: Exploring newer avenues using neutron activated (45)Ca.

Chakravarty R, Chakraborty S, Ram R, Nair KV, Rajeswari A, Sarma HD, Dash A.

Nucl Med Biol. 2016 Feb;43(2):140-9. doi: 10.1016/j.nucmedbio.2015.10.005. Epub 2015 Dec 2.

PMID:
26872438
21.

Increased Adoption of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention in U.S. Academic Medical Centers.

Padula WV, Mishra MK, Makic MB, Wald HL, Campbell JD, Nair KV, Valuck RJ.

Worldviews Evid Based Nurs. 2015 Dec;12(6):328-36. doi: 10.1111/wvn.12108. Epub 2015 Oct 13.

PMID:
26462012
22.

One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.

Simeone JC, Molife C, Marrett E, Frech-Tamas F, Effron MB, Nordstrom BL, Zhu YE, Keller S, Murphy BR, Nair KV, Vetrovec GW, Page RL 2nd, McCollam PL.

Am J Cardiovasc Drugs. 2015 Oct;15(5):337-50. doi: 10.1007/s40256-015-0147-y.

PMID:
26359016
23.

Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.

Page RL 2nd, Ghushchyan V, Read RA, Hartsfield CL, Koch BR 2nd, Nair KV.

Am J Cardiol. 2015 Nov 1;116(9):1321-8. doi: 10.1016/j.amjcard.2015.08.002. Epub 2015 Aug 14.

PMID:
26358510
24.

Incorporating real-world clinical practice in multiple sclerosis economic evaluations.

McQueen RB, Nair KV, Vollmer TL, Campbell JD.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):869-72. doi: 10.1586/14737167.2015.1081060. Epub 2015 Aug 20.

PMID:
26295727
25.

Hospital-Acquired Pressure Ulcers at Academic Medical Centers in the United States, 2008-2012: Tracking Changes Since the CMS Nonpayment Policy.

Padula WV, Makic MB, Wald HL, Campbell JD, Nair KV, Mishra MK, Valuck RJ.

Jt Comm J Qual Patient Saf. 2015 Jun;41(6):257-63.

PMID:
25990891
26.

Comparative effectiveness of quality improvement interventions for pressure ulcer prevention in academic medical centers in the United States.

Padula WV, Makic MB, Mishra MK, Campbell JD, Nair KV, Wald HL, Valuck RJ.

Jt Comm J Qual Patient Saf. 2015 Jun;41(6):246-56.

PMID:
25990890
27.

Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both.

Ghushchyan V, Nair KV, Page RL 2nd.

Vasc Health Risk Manag. 2014 Dec 24;11:25-34. doi: 10.2147/VHRM.S72331. eCollection 2015.

28.

Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population.

Saseen JJ, Ghushchyan V, Nair KV.

J Clin Hypertens (Greenwich). 2015 Feb;17(2):134-40. doi: 10.1111/jch.12453. Epub 2014 Dec 15.

29.

Determining the cost of obesity and its common comorbidities from a commercial claims database.

Padula WV, Allen RR, Nair KV.

Clin Obes. 2014 Feb;4(1):53-8. doi: 10.1111/cob.12041. Epub 2013 Nov 22.

PMID:
25425133
30.

Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension.

Wilson L, Nair KV, Saseen JJ.

J Clin Hypertens (Greenwich). 2014 Dec;16(12):864-8. doi: 10.1111/jch.12413. Epub 2014 Sep 25.

31.

Dynamic medication adherence modeling in primary prevention of cardiovascular disease: a Markov microsimulation methods application.

Slejko JF, Sullivan PW, Anderson HD, Ho PM, Nair KV, Campbell JD.

Value Health. 2014 Sep;17(6):725-31. doi: 10.1016/j.jval.2014.06.010. Epub 2014 Jul 28.

32.

Hidden costs associated with venous thromboembolism: impact of lost productivity on employers and employees.

Page RL 2nd, Ghushchyan V, Gifford B, Read RA, Raut M, Bookhart BK, Naim AB, Damaraju CV, Nair KV.

J Occup Environ Med. 2014 Sep;56(9):979-85. doi: 10.1097/JOM.0000000000000208.

PMID:
25046319
33.

Frequency of Continuous Glucose Monitoring Use and Change in Hemoglobin A1C for Adults with Type 1 Diabetes in a Clinical Practice Setting.

McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Campbell JD.

Endocr Pract. 2014 Oct;20(10):1007-15. doi: 10.4158/EP14027.OR.

PMID:
24793924
34.

Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.

Thompson LA, Saseen JJ, O'Bryant CL, Allen RR, Nair KV.

J Oncol Pharm Pract. 2015 Aug;21(4):258-67. doi: 10.1177/1078155214530177. Epub 2014 Apr 11.

PMID:
24727344
35.

Association between glycated hemoglobin and health utility for Type 1 diabetes.

McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD.

Patient. 2014;7(2):197-205. doi: 10.1007/s40271-014-0045-4.

PMID:
24458545
36.

Adherence to statins in primary prevention: yearly adherence changes and outcomes.

Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD.

J Manag Care Pharm. 2014 Jan;20(1):51-7.

37.

Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.

Saseen JJ, Ghushchyan V, Kaila S, Allen RR, Nair KV.

J Clin Hypertens (Greenwich). 2013 Dec;15(12):888-92. doi: 10.1111/jch.12197. Epub 2013 Sep 19.

38.

The economic burden of acute coronary syndromes for employees and their dependents: medical and productivity costs.

Page RL 2nd, Ghushchyan V, Gifford B, Read RA, Raut M, Crivera C, Naim AB, Damaraju CV, Nair KV.

J Occup Environ Med. 2013 Jul;55(7):761-7. doi: 10.1097/JOM.0b013e318297323a.

PMID:
23787565
39.

Patient-level medication regimen complexity across populations with chronic disease.

Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD.

Clin Ther. 2013 Apr;35(4):385-398.e1. doi: 10.1016/j.clinthera.2013.02.019. Epub 2013 Mar 29.

40.

Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.

Barnes CJ, Caon C, Foley JF, Friedman M, Menzin J, Nair KV, Nichols C, Olvey EL, Owens GM, Pill MW, Skrepnek GH, White LA, Zerkowski K.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S1-53. No abstract available.

PMID:
23383730
41.
42.

Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis.

Foley JF, Barnes CJ, Nair KV.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S16-23. Review.

43.

Work absences and expenditures for employees with autoimmune inflammatory diseases.

Nair KV, Naim AB, Draaghtel K, Van Den Bos J.

J Occup Environ Med. 2012 Oct;54(10):1268-74. doi: 10.1097/JOM.0b013e31825a36a0.

PMID:
22995815
44.

Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.

Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV.

Rheumatology (Oxford). 2012 Nov;51(11):2004-12. doi: 10.1093/rheumatology/kes183. Epub 2012 Jul 23.

PMID:
22829689
45.

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap.

Page RL 2nd, Ghushchyan V, Allen RR, Roper L, Beck D, Jonathan BH, Frech-Tamas F, Chan W, McQueen RB, Nair KV.

Drug Healthc Patient Saf. 2012;4:67-74. doi: 10.2147/DHPS.S32473. Epub 2012 Jul 10.

46.

Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.

Alford JC, Saseen JJ, Allen RR, Nair KV.

Pharmacotherapy. 2012 Jul;32(7):623-30. doi: 10.1002/j.1875-9114.2011.01090.x. Epub 2012 May 8.

PMID:
22570173
47.

Pharmacoeconomics and outcomes research degree-granting PhD programs in the United States.

Slejko JF, Libby AM, Nair KV, Valuck RJ, Campbell JD.

Res Social Adm Pharm. 2013 Jan-Feb;9(1):108-13. doi: 10.1016/j.sapharm.2012.03.002. Epub 2012 May 2.

PMID:
22554392
48.

Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan.

Nair KV, Frech-Tamas F, Jan S, Wolfe P, Allen RR, Saseen JJ.

J Health Care Finance. 2011 Winter;38(2):38-53.

PMID:
22372031
49.

An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures.

Pesa JA, Van Den Bos J, Gray T, Hartsig C, McQueen RB, Saseen JJ, Nair KV.

Patient Prefer Adherence. 2012;6:63-72. doi: 10.2147/PPA.S28396. Epub 2012 Jan 18.

50.

Utilization characteristics of spinal interventions.

Abbott ZI, Nair KV, Allen RR, Akuthota VR.

Spine J. 2012 Jan;12(1):35-43. doi: 10.1016/j.spinee.2011.10.005. Epub 2011 Dec 3.

PMID:
22138113

Supplemental Content

Loading ...
Support Center